Pharma and hospital-related stocks are seeing heightened investor interest today, March 24, 2025, following key developments. Alembic Pharma announced the successful completion of a US FDA inspection at its API-III facility in Karakhadi with zero Form 483 observations, underscoring strong regulatory compliance. Gland Pharma gained traction after Vanguard picked up 18.55 lakh shares, reflecting institutional confidence. Apollo Hospitals’ subsidiary made a strategic move by acquiring an 11.2% stake in Keimed for ₹625.23 crore, expanding its presence in healthcare distribution. Meanwhile, Fortis Healthcare received an injunction order related to its Shrimann Hospital acquisition, seen as a neutral legal update. Dr Reddy’s Laboratories, in a routine move, has scheduled its board meeting on May 9 to consider financial results and dividend declaration.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to risks, and readers should conduct their own research or consult a financial advisor before making any investment decisions.
